Kerala-based HLL Lifecare Limited, a mini ratna public sector undertaking with diversified business, will foray into molecular diagnostics area with a duplex test kit for chikungunya and dengue tests.

The new multiplex molecular diagnostic kit, based on PCR (polymerase chain reaction), was developed by HLL in collaboration with the Rajiv Gandhi Centre for Biotechnology, also based in Thiruvananthapuram, said a release here.

Currently, HLL Lifecare is in a tie-up with Kerala State Institute for Virology and Infectious Diseases, under the state government’s Ministry of Health and Family Welfare Department, for third-party validation of the diagnostic kits. The product will be launched in the market very soon.

“This kit comes as the latest offering from our portfolio to ease the burden of the common man,” HLL chairman and managing director Dr M Ayyappan.

The new product would facilitate conduct of the test with large throughput screening for management of diseases. It is going to be a handy tool in screening of patients on a large scale basis in an affordable manner, he said.

The 1966-founded HLL, the leading manufacturer of condoms, is strong-footed in the diagnostic business with its Hindlabs that provide a complete range of path lab services. The company is planning to extend the facility for other viral platforms as well.

HLL has a factory located at Manesar in Haryana, exclusively catering to the manufacturing of in-vitro diagnostic test kits. This unit had started with manufacture of pregnancy test kits and is currently into production of kits for dengue and malaria, among other infectious diseases.

The epidemic of chikungunya continues to resurface in the country every year, especially during the monsoon season. In 2010, as many as 48,176 clinically suspected cases were reported from 18 states/union territories (135 districts), according to the figures from the Planning Commission. Likewise, dengue is endemic to 31 states and UTs. In 2006, the country witnessed an outbreak of the disease with 12,317 cases and 184 deaths, from 270 districts. In 2010, a total of 28,292 cases and 110 deaths reported from 403 districts, recording the highest number in the last two decades.